肌层浸润性膀胱癌患者接受阿替利珠单抗联合吉西他滨和顺铂新辅助治疗:一项多中心、单臂、II期试验
这项多中心单臂II期试验评估了新辅助阿替利珠单抗联合吉西他滨和顺铂(GC)治疗肌层浸润性膀胱癌(MIBC)的疗效。44例入组患者中39例可评估,主要终点达到,27例(69%)达到<pT2N0,其中16例(41%)为pT0N0。最常见3-4级不良事件为中性粒细胞减少(16例,36%),3级免疫相关不良事件5例(11%),其中2例(5%)需全身激素治疗。
要点
- 39例可评估患者中27例(69%)达到<pT2N0,其中16例(41%)为pT0N0
- 达到<pT2N0的患者无复发,≥pT2N0患者中4例(11%)复发,中位随访16.5个月(范围7.0-33.7个月)
- 3-4级中性粒细胞减少16例(36%),3级免疫相关不良事件5例(11%),其中2例(5%)需全身激素
核心结论
- 新辅助GC联合阿替利珠单抗是MIBC有前景的方案,值得进一步研究。
- 达到<pT2N0的患者无复发生存改善。
- PD-L1阳性率低于已发表数据,限制了PD-L1作为预测生物标志物的结论。
研究设计与样本
- 多中心、单臂、II期试验。
- 入组44例MIBC(cT2-T4aN0M0)患者,39例可评估。
- 治疗方案:先给予一剂阿替利珠单抗,2周后每21天给予GC联合阿替利珠单抗共4周期,3周后再给予一剂阿替利珠单抗,随后行根治性膀胱切除术。
- 主要终点为非肌层浸润降期至<pT2N0。
主要发现
- 39例可评估患者中27例(69%)达到<pT2N0,其中16例(41%)为pT0N0。
- 达到<pT2N0的患者无复发;≥pT2N0患者中4例(11%)复发,中位随访16.5个月(范围7.0-33.7个月)。
- 1例拒绝根治性膀胱切除术,2例在术前发生转移性疾病,均被视为无应答者。
- 最常见3-4级不良事件为中性粒细胞减少(16例,36%)。
- 3级免疫相关不良事件发生在5例(11%)患者中,其中2例(5%)需全身激素治疗。
关键数值与推荐
- 主要终点达到:39例中27例(69%)<pT2N0,其中16例(41%)pT0N0。
- ≥pT2N0患者中4例(11%)复发,中位随访16.5个月(范围7.0-33.7个月)。
- 3-4级中性粒细胞减少16例(36%);3级免疫相关不良事件5例(11%),其中2例(5%)需全身激素。
- PD-L1阳性肿瘤4例(10%),均<pT2N0;PD-L1低或阴性肿瘤患者中34例中23例(68%)<pT2N0,34例中11例(32%)≥pT2N0(P=0.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- PD-L1阳性率低于已发表数据,限制了PD-L1作为预测生物标志物的结论。
- 原文结论指出该方案值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of the activity of atezolizumab (A) in metastatic BC, we tested neoadjuvant GC plus A for MIBC. METHODS: Eligible patients with MIBC (cT2-T4aN0M0) received a dose of A, followed 2 weeks later by GC plus A every 21 days for four cycles followed 3 weeks later by a dose of A before RC. The primary end point was non-muscle-invasive downstaging to < pT2N0. RESULTS: Of 44 enrolled patients, 39 were evaluable. The primary end point was met, with 27 of 39 patients (69%) < pT2N0, including 16 (41%) pT0N0. No patient with < pT2N0 relapsed and four (11%) with ≥ pT2N0 relapsed with a median follow-up of 16.5 months (range: 7.0-33.7 months). One patient refused RC and two developed metastatic disease before RC; all were considered nonresponders. The most common grade 3-4 adverse event (AE) was neutropenia (n = 16; 36%). Grade 3 immune-related AEs occurred in five (11%) patients with two (5%) requiring systemic steroids. The median time from last dose of chemotherapy to surgery was 7.8 weeks (range: 5.1-17 weeks), and no patient failed to undergo RC because of AEs. Four of 39 (10%) patients had programmed death-ligand 1 (PD-L1)-positive tumors and were all < pT2N0. Of the patients with PD-L1 low or negative tumors, 23 of 34 (68%) achieved < pT2N0 and 11 of 34 (32%) were ≥ pT2N0 (P = .3 for association between PD-L1 and < pT2N0). CONCLUSION: Neoadjuvant GC plus A is a promising regimen for MIBC and warrants further study. Patients with < pT2N0 experienced improved relapse-free survival. The PD-L1 positivity rate was low compared with published data, which limits conclusions regarding PD-L1 as a predictive biomarker.
引用
- Funt SA, Lattanzi M, Whiting K, et al. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol. 2022. PMID: 35089812. doi:10.1200/JCO.21.01485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。